Inhaled Isopropyl Alcohol Versus Placebo to Manage Nausea at Electronic Dance Music Festivals

POPULATION OF INTEREST

Participants will be recruited from electronic dance music (EDM) festivals in Canada. This population was chosen because festival participants often present to event medical staff with a complaint of nausea, in a setting where the availability of medical resources such as oral and intravenous anti-nauseants are more limited than an emergency department. Although the effectiveness of isopropyl alcohol pads as anti-nauseant therapy has been demonstrated in hospital emergency rooms, no prior studies, to the investigators' knowledge, have assessed outcomes in festival populations. This study will be conducted by adapting protocols from prior studies that examined the effects of inhaled isopropyl alcohol on patient-reported nausea and will add to the current state of knowledge by investigating a novel population.

EDM events are included in this study, because the investigators have long-standing experience working at these festivals as part of the main medical team, responsible for providing medical care to all festival participants. Odyssey Medical, the organization that oversees all medical staff at these EDM events, has granted the investigators permission to integrate the proposed research study into patient care at these festivals. This organization recruits multi-disciplinary volunteers (physicians, nurses, respiratory therapists, pharmacists, lifeguards, paramedics, and first aiders) to manage the medical needs of festival attendees.

PARTICIPANT SCREENING

Participants will verbally respond to screening questions, with responses recorded electronically by Research Personnel #1 (aka "the assessor") on a secure Google Form (printed copies will be available as back-up). Individuals who satisfy all inclusion/exclusion criteria will continue in the study, while those who do not meet criteria will receive standard medical care as needed (e.g. oral or intravenous anti-nauseant).

Consent to participate in the study will be obtained with a signature, after review of a written consent form. For the consent process, the investigators will have a witness from the medical team. For all individuals with a complaint of nausea, the assessor will outline the purpose of the study, clarify risks/benefits, and highlight that participation is voluntary and can be withdrawn, before seeking consent. Given that festival participants may be intoxicated with substances, Research Personnel #1 will determine whether the participant has the mental capacity to continue with the study. Research Personnel #1 will confirm the person's name, sex, and age. If the participant is unable to report their name, sex, and age accurately (using the patient's chart as a comparator or a friend/family member), then this implies that the participant is not oriented enough (e.g., potentially too intoxicated) to continue the study; this participant would not continue with the study. Also, if the participant cannot verbalize a pre-treatment nausea score (e.g., tries to communicate with fingers or body language, asks a friend to translate, etc.), then this implies that they may be too intoxicated to use their own cognitive capacity to determine a specific number and then verbalize it; this participant would not continue with the study.

If consent is granted, the following information about the participant will be collected throughout the study:

• Numerical identification number (will be assigned based on the order of recruitment, e.g. participant 001, participant 002)

• Age

• Sex

• Self-reported alcohol consumed

• Self-reported recreational drugs ingested

• Self-reported other suspected contributors of nausea (e.g. migraine, head injury, pregnancy, infection)

• Pre-treatment nausea level (0-11)

• Absence/presence of emesis prior to treatment

• 10-minute post-treatment nausea level (0-11) staff with a complaint of nausea, in a setting where the availability of medical
 resources such as oral and intravenous anti-nauseants are more limited than an emergency
 department. Although the effectiveness of isopropyl alcohol pads as anti-nauseant therapy
 has been demonstrated in hospital emergency rooms, no prior studies, to the
 investigators' knowledge, have assessed outcomes in festival populations. This study will
 be conducted by adapting protocols from prior studies that examined the effects of
 inhaled isopropyl alcohol on patient-reported nausea and will add to the current state of
 knowledge by investigating a novel population.
 

EDM events are included in this study, because the investigators have long-standing
 experience working at these festivals as part of the main medical team, responsible for
 providing medical care to all festival participants. Odyssey Medical, the organization
 that oversees all medical staff at these EDM events, has granted the investigators
 permission to integrate the proposed research study into patient care at these festivals.
 This organization recruits multi-disciplinary volunteers (physicians, nurses, respiratory
 therapists, pharmacists, lifeguards, paramedics, and first aiders) to manage the medical
 needs of festival attendees.
 
 PARTICIPANT SCREENING
 
 Participants will verbally respond to screening questions, with responses recorded
 electronically by Research Personnel #1 (aka "the assessor") on a secure Google Form
 (printed copies will be available as back-up). Individuals who satisfy all
 inclusion/exclusion criteria will continue in the study, while those who do not meet
 criteria will receive standard medical care as needed (e.g. oral or intravenous
 anti-nauseant).
 
 Consent to participate in the study will be obtained with a signature, after review of a
 written consent form. For the consent process, the investigators will have a witness from
 the medical team. For all individuals with a complaint of nausea, the assessor will
 outline the purpose of the study, clarify risks/benefits, and highlight that
 participation is voluntary and can be withdrawn, before seeking consent. Given that
 festival participants may be intoxicated with substances, Research Personnel #1 will
 determine whether the participant has the mental capacity to continue with the study.
 Research Personnel #1 will confirm the person's name, sex, and age. If the participant is
 unable to report their name, sex, and age accurately (using the patient's chart as a
 comparator or a friend/family member), then this implies that the participant is not
 oriented enough (e.g., potentially too intoxicated) to continue the study; this
 participant would not continue with the study. Also, if the participant cannot verbalize
 a pre-treatment nausea score (e.g., tries to communicate with fingers or body language,
 asks a friend to translate, etc.), then this implies that they may be too intoxicated to
 use their own cognitive capacity to determine a specific number and then verbalize it;
 this participant would not continue with the study.
 
 If consent is granted, the following information about the participant will be collected
 throughout the study:
 

• Numerical identification number (will be assigned based on the order of recruitment,
 e.g. participant 001, participant 002)
 

• Age
 

• Sex
 

• Self-reported alcohol consumed
 

• Self-reported recreational drugs ingested
 

• Self-reported other suspected contributors of nausea (e.g. migraine, head injury,
 pregnancy, infection)
 

• Pre-treatment nausea level (0-11)
 

• Absence/presence of emesis prior to treatment
 

• 10-minute post-treatment nausea level (0-11)

• Absence/presence of emesis post-treatment

• Any side effects or additional symptoms post-treatment

No uniquely identifying information such as name, birth date, or Provincial Health Care number will be recorded at any point of the study to preserve anonymity. Age and sex will be recorded alongside screening criteria and will be linked with each individual's data for future subgroup analyses, but this broad information is not expected to interfere with anonymity.

PARTICIPANT RANDOMIZATION

Included participants will be assigned to one of two study arms through randomization, facilitated by an electronic random number generator operated by Research Personnel #2 (i.e. "the intervention provider"), who will not be present for the baseline screening assessment.

INTERVENTION DELIVERY

Research Personnel #2 will then deliver the intervention according to the assigned study arm. Participants in Arm 1 will nasally inhale an isopropyl alcohol pad with 10 inhalations (intervention). Participants in Arm 2 will nasally inhale a sterile saline pad of similar appearance with 10 inhalations (placebo). Research Personnel #2 will remove the packaging out of participants' sight, in order to ensure participants are blinded to the identity of the inhaled substance. The isopropyl alcohol pad, or sterile saline pad, will be held within 2cm of participants' nares to ensure delivery during inhalations, as a 2018 study demonstrated success using isopropyl alcohol aromatherapy as an anti-nauseant when inhaled from 1-2cm from the nares.

According to a 2002 study, isopropyl alcohol pad inhalation, dosed at 3 inhalations every 5 minutes for 3 doses, was not significantly different than standard anti-nauseant treatment for relief of nausea. 10 inhalations exceeds the 9-dose total reported in the paper, and a one time bolus dose of 10 inhalations, for this population and festival context, is more feasible in terms of patient compliance and patient flow in the main medical area. Two other studies' protocols involved inhaling isopropyl alcohol, as many times as participants desired, within a few minutes. With all protocols taken into consideration, the investigators have determined that 10 inhalations is an appropriate threshold for potential anti-nauseant effect.

OUTCOME ASSESSMENT

After Research Personnel #2 (aka "the intervention provider") has ensured that the intervention/placebo has been inhaled, they will leave the participant's bedside to prevent them from biasing any subsequent outcome assessment, given their knowledge of the study arm. The intervention provider will not disclose the identity of the inhaled substance to the participant nor to the assessor.

10 minutes post-inhalation, Research Personnel #1 (aka "the assessor"), will return and assess the participant's nausea using the same 11-point numerical scale prior to treatment. Participants will also be asked to report any new symptoms in order to aid the identification of possible adverse outcomes. Presence or absence of vomiting pre- and post-intervention will also be recorded.

After the data collection is complete, both the intervention and control arms will be offered further treatment by medical staff if their nausea has not subsided. These "rescue" (additional) therapies may include oral and/or intravenous anti-nauseants. The need for rescue medications will be recorded.

DATA ANALYSIS

For primary and secondary outcomes, data will be analyzed with a one-tailed repeated-measures t-test to see if there are any differences in self-reported nausea pre-intervention and 10-minutes post-intervention, between the means of the treatment arms.

Subgroup analyses will be performed, via repeated-measures t-test to see if there are any differences between the means of the treatment arms, by male sex, female sex, age (18-25, 25-34, 35+), alcohol ingested, any recreational substance ingested, alcohol plus other any recreational substance ingested, and self-reported other suspected contributors of nausea.

SAMPLE SIZE

Sample size for each group was calculated with the assumption that the outcome data fits a ratio scale (nausea is rated on a continuum, ranging from 0 to 10).

A sample size, for adequate study power, was performed with the following parameters:

• Study group design: two independent study groups

• Primary endpoint: continuous (means)

• Anticipated mean for isopropyl alcohol swab group: 3 +/- 3

• Anticipated mean for placebo group: 5

• Alpha: 0.05

• Power: 0.8

Previous work in 2016 found the median nausea score for the isopropyl alcohol pad group was 3 and for the placebo group, 6, in the emergency department. The investigators lowered the placebo group by 1 point, to 5, to be conservative in calculations. A 2018 study found that the standard deviation was up to 30, on scale of 0 to 100, for all treatment groups (when comparing inhaled isopropyl alcohol + oral ondansetron, inhaled isopropyl alcohol + oral placebo, and inhaled placebo + oral ondansetron); therefore, the investigators assume a standard deviation of up to 3, in their scale from 0 to 10.

The investigators calculated a minimum sample size of 46 to power the study. Given that the sample size is large enough, the central limit theorem supports the normality assumption; therefore, a parametric test was selected (repeated-measures t-test) for statistical analyses.